The results showed that tamoxifen and fulvestrant plus FMD could lower the level of IGF1, insulin and leptin, and inhibit AKT-mTOR signaling via upregulating epidermal growth factor 1, the expression of which is associated with good prognosis in patients with BC, and PTEN, a negative regulator of AKT-mTOR signaling, and ultimately suppress tumor progression in mice. This evidence concerns the gene AKT1 and breast cancer.